Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b 1178,"de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84.",peripheral nervous system integrity trait,peripheral nervous system integrity trait,RS:0002061,LEW.1AV1/Kini,male,200 days to 98 days,41,,CMO:0001522,percentage of study population developing experimental autoimmune neuritis during a period of time,,,,100,%,,,MMO:0000162,ex vivo visual assessment,,0.0,,,,,peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) ,84522,peripheral nerve myelin (2 mg) ,Freund's complete adjuvant (100 ul) 1178,"de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84.",peripheral nervous system integrity trait,peripheral nervous system integrity trait,RS:0002061,LEW.1AV1/Kini,male,200 days to 98 days,6,,CMO:0001522,percentage of study population developing experimental autoimmune neuritis during a period of time,,,,100,%,,,MMO:0000162,ex vivo visual assessment,,0.0,,,,,peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) ,84536,peripheral myelin protein 2 peptide 58-81 (100 ug) ,Freund's complete adjuvant (100 ul)